Overview

Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment nave, Cutaneous Melanoma Study

Status:
RECRUITING
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
The association between microbiota and response to ICI-based therapy reflects the ability of bacterial metabolites to upregulate MHC class I APM component expression and/or function in cancer cells, leading to their elimination by the host's immune system. Thus, the aim of this project is to evaluate the ability of anti PD-1 combined with postbiotic, that here will be a coadjuvant of a standard immunotherapy to upregulate MHC class I APM component expression and/or function in cancer cells compared to anti PD-1 alone in first line advanced melanoma patients.
Phase:
NA
Details
Lead Sponsor:
Azienda Ospedaliera di Perugia
Collaborator:
Istituto Clinico Humanitas